Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2021 Nov 27

PMID 34834295

Citations 10

Authors

Zdenek Kejik

Robert Kaplanek

Petr Dytrych

Michal Masarik

Katerina Vesela

Nikita Abramenko

David Hoskovec

Martina Vasakova

Jarmila Kralova

Pavel Martasek

Milan Jakubek

Affiliations

Soon will be listed here.

Abstract

Designing optimal (neo)adjuvant therapy is a crucial aspect of the treatment of non-small-cell lung carcinoma (NSCLC). Standard methods of chemotherapy, radiotherapy, and immunotherapy represent effective strategies for treatment. However, in some cases with high metastatic activity and high levels of circulating tumour cells (CTCs), the efficacy of standard treatment methods is insufficient and results in treatment failure and reduced patient survival. CTCs are seen not only as an isolated phenomenon but also a key inherent part of the formation of metastasis and a key factor in cancer death. This review discusses the impact of NSCLC therapy strategies based on a meta-analysis of clinical studies. In addition, possible therapeutic strategies for repression when standard methods fail, such as the administration of low-toxicity natural anticancer agents targeting these phenomena (curcumin and flavonoids), are also discussed. These strategies are presented in the context of key mechanisms of tumour biology with a strong influence on CTC spread and metastasis (mechanisms related to tumour-associated and -infiltrating cells, epithelial-mesenchymal transition, and migration of cancer cells).

Citing Articles

Curcumin: A Potential Weapon in the Prevention and Treatment of Head and Neck Cancer.

Vesela K, Kejik Z, Masarik M, Babula P, Dytrych P, Martasek P ACS Pharmacol Transl Sci. 2024; 7(11):3394-3418.

PMID: 39539276 PMC: 11555516. DOI: 10.1021/acsptsci.4c00518.

Investigating antibacterial and anti-inflammatory properties of synthetic curcuminoids.

Vesela K, Kejik Z, Abramenko N, Kaplanek R, Jakubek M, Petrlova J Front Med (Lausanne). 2024; 11:1478122.

PMID: 39534226 PMC: 11554473. DOI: 10.3389/fmed.2024.1478122.

Cyanine dyes in the mitochondria-targeting photodynamic and photothermal therapy.

Kejik Z, Hajduch J, Abramenko N, Vellieux F, Vesela K, Leischner Fialova J Commun Chem. 2024; 7(1):180.

PMID: 39138299 PMC: 11322665. DOI: 10.1038/s42004-024-01256-6.

New insights into the correlations between circulating tumor cells and target organ metastasis.

Zhan Q, Liu B, Situ X, Luo Y, Fu T, Wang Y Signal Transduct Target Ther. 2023; 8(1):465.

PMID: 38129401 PMC: 10739776. DOI: 10.1038/s41392-023-01725-9.

Significance of circulating tumor cells in lung cancer: a narrative review.

Hamilton G, Rath B, Stickler S Transl Lung Cancer Res. 2023; 12(4):877-894.

PMID: 37197632 PMC: 10183408. DOI: 10.21037/tlcr-22-712.

References

Aceto N, Bardia A, Miyamoto D, Donaldson M, Wittner B, Spencer J . Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014; 158(5):1110-1122. PMC: 4149753. DOI: 10.1016/j.cell.2014.07.013. View

Belcaro G, Hosoi M, Pellegrini L, Appendino G, Ippolito E, Ricci A . A controlled study of a lecithinized delivery system of curcumin (Meriva®) to alleviate the adverse effects of cancer treatment. Phytother Res. 2013; 28(3):444-50. DOI: 10.1002/ptr.5014. View

de Lazaro I, Mooney D . Obstacles and opportunities in a forward vision for cancer nanomedicine. Nat Mater. 2021; 20(11):1469-1479. DOI: 10.1038/s41563-021-01047-7. View

Giancotti F . Mechanisms governing metastatic dormancy and reactivation. Cell. 2013; 155(4):750-64. PMC: 4354734. DOI: 10.1016/j.cell.2013.10.029. View

Wan Mohd Tajuddin W, Lajis N, Abas F, Othman I, Naidu R . Mechanistic Understanding of Curcumin's Therapeutic Effects in Lung Cancer. Nutrients. 2019; 11(12). PMC: 6950067. DOI: 10.3390/nu11122989. View

Taverna S, Giallombardo M, Pucci M, Flugy A, Manno M, Raccosta S . Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth: a possible role for exosomal disposal of miR-21. Oncotarget. 2015; 6(26):21918-33. PMC: 4673136. DOI: 10.18632/oncotarget.4204. View

Farsad-Naeimi A, Alizadeh M, Esfahani A, Aminabad E . Effect of fisetin supplementation on inflammatory factors and matrix metalloproteinase enzymes in colorectal cancer patients. Food Funct. 2018; 9(4):2025-2031. DOI: 10.1039/c7fo01898c. View

Kirwan C, Descamps T, Castle J . Circulating tumour cells and hypercoagulability: a lethal relationship in metastatic breast cancer. Clin Transl Oncol. 2019; 22(6):870-877. PMC: 7188731. DOI: 10.1007/s12094-019-02197-6. View

Hirose T, Murata Y, Oki Y, Sugiyama T, Kusumoto S, Ishida H . Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer. Oncol Res. 2012; 20(2-3):131-7. DOI: 10.3727/096504012x13473664562583. View

10.

Scagliotti G, Gatti E, Ferrari G, Mutti L, Pozzi E . Tnp-alpha determination in serum and pleural effusion in patients with lung-cancer. Int J Oncol. 2011; 6(1):147-51. View

11.

Chen A, Jiang P, Zeb F, Wu X, Xu C, Chen L . EGCG regulates CTR1 expression through its pro-oxidative property in non-small-cell lung cancer cells. J Cell Physiol. 2020; 235(11):7970-7981. DOI: 10.1002/jcp.29451. View

12.

Hariri M, Gholami A, Mirhafez S, Bidkhori M, Sahebkar A . A pilot study of the effect of curcumin on epigenetic changes and DNA damage among patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, clinical trial. Complement Ther Med. 2020; 51:102447. DOI: 10.1016/j.ctim.2020.102447. View

13.

Santilli G, Piotrowska I, Cantilena S, Chayka O, DAlicarnasso M, Morgenstern D . Polyphenon [corrected] E enhances the antitumor immune response in neuroblastoma by inactivating myeloid suppressor cells. Clin Cancer Res. 2013; 19(5):1116-25. DOI: 10.1158/1078-0432.CCR-12-2528. View

14.

Wu W, Onn A, Isobe T, Itasaka S, Langley R, Shitani T . Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther. 2007; 6(2):471-83. DOI: 10.1158/1535-7163.MCT-06-0416. View

15.

Ko H, So Y, Jeon H, Jeong M, Choi H, Ryu S . TGF-β1-induced epithelial-mesenchymal transition and acetylation of Smad2 and Smad3 are negatively regulated by EGCG in human A549 lung cancer cells. Cancer Lett. 2013; 335(1):205-13. DOI: 10.1016/j.canlet.2013.02.018. View

16.

Sharma S, Zhuang R, Long M, Pavlovic M, Kang Y, Ilyas A . Circulating tumor cell isolation, culture, and downstream molecular analysis. Biotechnol Adv. 2018; 36(4):1063-1078. PMC: 5971144. DOI: 10.1016/j.biotechadv.2018.03.007. View

17.

Naidu S, Shi L, Magee P, Middleton J, Lagana A, Sahoo S . PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF-kB pathways. Sci Rep. 2017; 7(1):15441. PMC: 5684387. DOI: 10.1038/s41598-017-14843-6. View

18.

Ortiz-Otero N, Clinch A, Hope J, Wang W, Reinhart-King C, King M . Cancer associated fibroblasts confer shear resistance to circulating tumor cells during prostate cancer metastatic progression. Oncotarget. 2020; 11(12):1037-1050. PMC: 7105166. DOI: 10.18632/oncotarget.27510. View

19.

Liu J, Xu Y, Yu M, Liu Z, Xu Y, Ma G . Increased Stromal Infiltrating Lymphocytes are Associated with Circulating Tumor Cells and Metastatic Relapse in Breast Cancer Patients After Neoadjuvant Chemotherapy. Cancer Manag Res. 2020; 11:10791-10800. PMC: 6939396. DOI: 10.2147/CMAR.S220327. View

20.

Ma Z, Xia Y, Hu C, Yu M, Yi H . Quercetin promotes the survival of granulocytic myeloid-derived suppressor cells via the ESR2/STAT3 signaling pathway. Biomed Pharmacother. 2020; 125:109922. DOI: 10.1016/j.biopha.2020.109922. View